Baxter International Inc. (NYSE:BAX) and Merrimack Pharmaceuticals, Inc.
(Nasdaq:MACK) today jointly announced an exclusive license and
collaboration agreement for the development and commercialization of
MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.''
Through the agreement, Baxter gains exclusive commercialization rights
for all potential indications of MM-398 outside the United States and
Taiwan, and Merrimack retains commercialization rights in the United
States; the rights in Taiwan are held separately.
Data Presented as Part of Meta-Analysis Showing MM-121's Favorable Impact on Progression Free Survival in 38-54 Percent of Patients With Ovarian, Lung and Breast Cancers Across Three Phase 2 Studies
MADRID, Spain, Sept.
Sign-up for Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.